Perrigo Company Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on March 30, 2015, regarding Perrigo Company Plc's acquisition of Omega Pharma Invest NV. The filing details the completion of the purchase of 95.77% of Omega's outstanding shares, the assumption of Omega's debt obligations, and key personnel appointments.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Total cash consideration of EUR 1,845,983,131 plus EUR 62,479,261 in accrued interest. Additionally, 5,397,711 shares of Perrigo stock were issued as non-cash consideration.
- Debt Assumed: Perrigo assumed all outstanding indebtedness of Omega, including:
- EUR 135,043,889 of 5.1045% senior notes due 2023.
- USD 20,000,000 (approx. EUR 16,247,000) of 6.19% senior notes due 2016.
- EUR 600,000,000 in retail bonds (EUR 300M due 2017, EUR 180M due 2017, EUR 120M due 2019).
- Approximately EUR 500,000,000 available under a revolving credit facility (subsequently terminated).
- Approximately EUR 50,000,000 available under overdraft facilities.
- Liquidity and Cash Flow: The filing does not provide specific post-transaction liquidity or cash flow metrics for Perrigo, only the cash outflow for the acquisition.
Material Changes
The primary material change is the consolidation of Omega Pharma into Perrigo. This resulted in a significant increase in Perrigo's debt load due to the assumption of Omega's senior notes and retail bonds. The transaction also triggered a change of control offer for Omega's 2016 and 2023 notes and the termination of Omega's revolving credit facility.
Management Commentary, Risks, and Unusual Items
- Personnel Changes: Marc Coucke, former CEO of Omega, was appointed Executive Vice President and General Manager of the Omega Pharma business unit. He also entered into an indefinite Consultancy Agreement with Omega.
- Compensation Arrangement: Under the Consultancy Agreement, Mr. Coucke receives an annual fixed reimbursement of EUR 1,200,000 plus a board-determined bonus. The agreement includes a 12-month tail period for non-solicitation.
- Unregistered Securities: The issuance of Perrigo shares to Alychlo NV was not registered under the Securities Act, relying on Section 4(2) exemptions.
Investor Verification Checklist
- Verify the total pro-forma debt load of Perrigo following the assumption of Omega's EUR 600M+ in bonds and senior notes.
- Confirm the status of the change of control offer for Omega's 2016 and 2023 notes and any resulting redemption activity.
- Review the terms of the Consultancy Agreement with Marc Coucke to assess ongoing compensation obligations and potential conflicts of interest.
- Assess the impact of the terminated revolving credit facility on Omega's short-term liquidity management.